EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Neprilysin as a Biomarker: Challenges and Opportunities

Noemi Pavo, Suriya Prausmüller, Philipp E Bartko, Georg Goliasch, Martin Hülsmann

Cardiac Failure Review · 14.08.2020 · 6

DOI: 10.15420/cfr.2019.21 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cardiac Failure Review, online erschienen am 14.08.2020. Verfasst von Noemi Pavo und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine II, Division of Cardiology, Medical University of Vienna Vienna, Austria. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Neprilysin (NEP) inhibition is a successful novel therapeutic approach in heart failure with reduced ejection fraction. Assessing individual NEP status might be important for gathering insights into mechanisms of disease and optimising individualised patient care. NEP is a zinc-dependent multisubstrate-metabolising oligoendopeptidase localised in the plasma membrane with the catalytic site facing the extracellular space. Although NEP activity in vivo is predominantly tissue-based, NEP can be released into the circulation via ectodomain shedding and exosomes. Attempts to determine circulating NEP concentrations and activity have not yet resulted in convincingly coherent results relating NEP biomarkers to heart failure disease severity or outcomes. NEP is naturally expressed on neutrophils, opening up the possibility of measuring a membrane-associated form with integrity. Small studies have linked NEP expression on neutrophils with inflammatory state and initial data might indicate its role in heart failure with reduced ejection fraction. Future studies need to assess the regulation of systemic NEP activity, which is assumed to be tissue-based, and the relationship of NEP activation with disease state. The relationship between tissue NEP activity and easily accessible circulating NEP biomarkers and the impact of the latter remains to be established.

Schlagwörter

Stichwörter der Autor:innen

Neprilysinangiotensin receptor neprilysin inhibitorbiomarkerheart failuresacubitril/valsartan

Autor:innen und Institutionen

  • Department of Internal Medicine II, Division of Cardiology, Medical University of Vienna Vienna, Austria.

Zitieren

APA

Pavo, N., Prausmüller, S., Bartko, P. E., Goliasch, G., & Hülsmann, M. (2020). Neprilysin as a Biomarker: Challenges and Opportunities. Cardiac Failure Review, 6. https://doi.org/10.15420/cfr.2019.21

Vancouver

Pavo N, Prausmüller S, Bartko PE, Goliasch G, Hülsmann M. Neprilysin as a Biomarker: Challenges and Opportunities. Cardiac Failure Review. 2020;6. doi:10.15420/cfr.2019.21

BibTeX
@article{Pavo2020,
  author = {Pavo, Noemi and Prausmüller, Suriya and Bartko, Philipp E and Goliasch, Georg and Hülsmann, Martin},
  title = {Neprilysin as a Biomarker: Challenges and Opportunities},
  journal = {Cardiac Failure Review},
  year = {2020},
  volume = {6},
  doi = {10.15420/cfr.2019.21}
}
Kostenlos starten →